Dr. Herman Weiss
Oct 11, 2026
Welcome back to The Pause Collective Science Review - the twice-a-week edition where I read the new menopause and PMOS research so you don't have to. Four papers this cycle, and a theme I did not plan but could not ignore: the body's history leaves clues, and medicine is finally learning to read them.
1. Irregular periods in midlife are a heart-risk signal - and the reason matters
Researchers asked a deceptively simple question: if a woman's periods are irregular in mid-adulthood, does it matter WHY? Using the Nurses' Health Study II cohort - 52,655 premenopausal women followed for up to 26 years, with 1,007 cardiovascular events along the way - they separated functional hypothalamic amenorrhea (FHA: irregular or absent periods without PMOS traits, typically paired with low body weight or heavy exercise) from other causes of irregular cycles.
The finding: women with the FHA pattern in mid-adulthood had a 62% higher risk of cardiovascular disease (hazard ratio 1.62, confidence interval 1.01-2.59), driven by nearly double the risk of coronary heart disease (HR 1.91). They also had an 86% higher risk of type 2 diabetes. Women whose cycles were irregular for OTHER reasons (including PMOS-like traits) had more cholesterol, blood pressure, and diabetes trouble - but not more heart attacks or strokes. And FHA in early adulthood, before about age 35, did not predict later events.
What this means for you: your menstrual history is not just a fertility story - it is a vital sign. If your periods were irregular or absent in your late 30s and 40s, especially alongside low weight or intense training, that is worth mentioning to your doctor the same way you would mention a family history of heart disease. For my PMOS readers: this study deliberately separated PMOS-type irregularity from FHA, and the risk profiles came out different. PMOS-type irregular cycles pointed at metabolic risk - cholesterol, blood pressure, blood sugar - which is exactly the terrain we already watch. Know which pattern is yours, because the follow-up differs.
The limits: this is an observational cohort of (mostly white) US nurses, the FHA group was small (that confidence interval nearly touches 1), and the phenotype came from questionnaires, not hormone panels. Association, not proof - but a well-done association in a very long-running cohort.
(Shufelt CL, Stuart JJ, Karam J, et al. Functional Hypothalamic Amenorrhea Phenotype and Cardiovascular Disease Risk. J Clin Endocrinol Metab, 2026. doi:10.1210/clinem/dgag405)
2. The PMOS gene map keeps growing - and it points at menopause too
Parker and Urbanek published a 2026 update on the genetic architecture of PMOS in Fertility and Sterility. Pooling 17 genome-wide association studies, researchers have now identified 120 genomic regions significantly associated with PMOS. Thirty-eight of them replicate in at least two independent cohorts, and most of those replicated regions hold up across multiple ancestries.
What are those genes doing? The list reads like a tour of everything we talk about here: gonadotropin secretion and action, follicle development, sex hormone function, adiposity, insulin signaling, type 2 diabetes, lipid and cholesterol levels - and, notably, age at menopause.
What this means for you: PMOS is not one disease, and genetics now proves it at scale. Different women arrive at the diagnosis through different biological doors, which is why one-size-fits-all advice keeps failing. For this community specifically: the same genetic regions implicated in PMOS also help set the timing of menopause. The biology of these two life stages is entangled - one more reason I cover them together. Today this changes no prescription; there is no clinical genetic test for PMOS. But this is how future subtypes and targeted treatments get built.
The limits: GWAS finds associations, not destiny - most of these regions each nudge risk only slightly, and the underlying data still skew toward European ancestries even though replication looks broader.
(Parker C, Urbanek M. Current Understanding of Genetic Architecture of Polyendocrine Metabolic Ovarian Syndrome (PMOS) - 2026 Update. Fertil Steril, 2026. doi:10.1016/j.fertnstert.2026.09.013)
3. Keto for PMOS: a small trial with big numbers
A single-center randomized trial in Frontiers in Nutrition put 60 women with PMOS (PCOS) on either a ketogenic diet (30 women: 70-75% fat, under 50 g of carbs a day) or a Mediterranean-style diet (30 women), same calories, a 500-kcal daily deficit, for 12 weeks. Ketosis was verified with blood and urine testing, so this was real keto, not wishful keto.
The results were striking. Menstrual regularity was restored in 96.7% of the keto group versus 66.7% of the Mediterranean group - a number needed to treat of about 3. The keto group lost far more weight (16 kg versus 6 kg), waist circumference (17 cm versus 6 cm), and visceral fat, with better fasting insulin, insulin resistance (HOMA-IR), and triglycerides. Both diets were safe over 12 weeks, with no serious adverse events and everyone completing the trial. The authors themselves suggest a sequential strategy: keto as a short metabolic reset, then transition to a Mediterranean pattern for the long haul.
What this means for you: if you have PMOS and struggle with insulin resistance, a supervised ketogenic phase is a legitimate thing to discuss with your doctor or dietitian - the trial used monitoring you should have too. And note that the Mediterranean arm was no slouch: two-thirds of those women also restored regular cycles. Food is medicine here either way; the question is intensity and sequencing.
The limits, and they matter: 60 women, one center, 12 weeks, open-label, and explicitly exploratory. We do not know what happens at month 13, or to fertility outcomes, or outside this population. Big numbers in a small trial are a reason for a bigger trial, not a reason to crown a winner.
(Wang M, Xie L, Ma L, Zhang C. Efficacy of ketogenic diet on glycemic-lipid metabolism and menstrual regularity in women with polycystic ovary syndrome: a randomized controlled trial. Front Nutr, 2026. doi:10.3389/fnut.2026.1920489)
4. Where fat sits shapes menopause symptoms - and estradiol is the middleman
A cross-sectional study from Shanghai (Frontiers in Endocrinology) measured 600 women aged 40-60, staged by STRAW+10 criteria, and asked how body composition relates to menopause symptom burden (Kupperman Index). Waist-to-hip ratio - where the fat sits - was independently associated with worse symptoms. Overall body fat percentage showed a weaker association. The clever part: mediation analysis suggested estradiol explains about 17.8% of the waist-to-hip-symptom link, while it mediated nothing for total body fat.
What this means for you: central, abdominal fat is metabolically and hormonally active in a way that peripheral fat is not - it both responds to falling estrogen and feeds back into how that fall feels. This is one more honest reason that the waistline conversation in midlife is about symptoms and long-term health, not appearance. And it reframes the goal: you cannot spot-reduce, but the usual boring levers (protein, resistance training, sleep, walking after meals) move exactly this fat depot.
The limits: cross-sectional, single-center, bioimpedance body-composition estimates, and a subjective symptom score. Mediation analysis in a snapshot of data cannot prove the estradiol pathway - it is a plausible mechanism, not a demonstrated one.
(Wang X, Yang D, Li J, Wang Y. Estradiol mediates the association of waist-to-hip ratio, but not body fat percentage, with menopause-related symptoms in Chinese women aged 40-60 years. Front Endocrinol (Lausanne), 2026. doi:10.3389/fendo.2026.1960475)
What is trending
The Menopause Society's 2026 Annual Meeting opens October 20-24 in San Diego, and the pre-meeting press releases are starting. The one making waves: a scoping review of ADHD medications (lisdexamfetamine and atomoxetine) for perimenopausal brain fog. The honest read: women reported feeling sharper and more on top of daily life, but objective cognitive tests did not move, and the Society itself says it is too early to recommend these medications for this use. If you see "ADHD drugs cure menopause brain fog" headlines in the next two weeks, now you know what the data actually says. Expect more meeting headlines - I will cover what matters.
The European estrogen shortage I have flagged before has escalated into a full supply story. Euronews reports that Spain's shortage of Lenzetto (a transdermal estradiol spray) cascaded into patches and gels (Evopad, Estradot, Bijuva are all affected), the EMA is weighing EU-coordinated measures, and the manufacturer admits it may not fully meet demand through 2027 - with relief in Spain expected to start only in late November. If you are in Europe and your pharmacy is out, do not wait and suffer silently: ask about alternative formulations now, before the queue gets longer.
The PMOS rename keeps rolling through the clinical press - Contemporary OB/GYN ran "PCOS is officially PMOS, but why?" this week - which tells me we are in the adoption phase now: the debate has moved from "should it change?" to "how do we implement it?" And an Australian piece on "unbridled rage" and other menopause symptoms doctors rarely discuss was widely shared - the conversation keeps widening past hot flashes, which is healthy.
A transparency note, as always: the above is grounded in news coverage and press releases I could read directly. I did not directly browse TikTok or Reddit threads this cycle, so I am not claiming to represent what those feeds showed today.
One cross-reference: Issue 8, published two days ago, covered the new ACP guideline on treating hot flashes - if you missed it, that is the one to catch up on.
Until the next one,
Dr. Herman Weiss
Medical Disclaimer
The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health-care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here. Use of this content does not create a doctor-patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.